Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
F BérardM C Ferrier Le BouedecLaurence BouilletZ ReguiaiAnnick BarbaudF CambazardBrigitte MilpiedB PelvetI KasujeeH GharbiJean-Philippe LacourPublished in: The British journal of dermatology (2018)
Omalizumab was efficacious in patients with CSU nonresponsive to H1-antihistamines. The UCT was a reliable tool for disease assessment and the scores correlated well with UAS7. This study does not support the usefulness of d-dimer to monitor long-term disease prognosis in adult urticaria; however, it may indicate patients who respond to omalizumab.